Keros Therapeutics (KROS) Enterprise Value (2019 - 2025)
Keros Therapeutics (KROS) has disclosed Enterprise Value for 7 consecutive years, with -$287.4 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Enterprise Value rose 48.67% year-over-year to -$287.4 million, compared with a TTM value of -$287.4 million through Dec 2025, up 48.67%, and an annual FY2025 reading of -$287.4 million, up 48.67% over the prior year.
- Enterprise Value was -$287.4 million for Q4 2025 at Keros Therapeutics, up from -$693.5 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$215.6 million in Q2 2022 and bottomed at -$720.5 million in Q1 2025.
- Average Enterprise Value over 5 years is -$376.5 million, with a median of -$305.0 million recorded in 2023.
- The sharpest move saw Enterprise Value crashed 368.11% in 2021, then skyrocketed 48.67% in 2025.
- Year by year, Enterprise Value stood at -$230.0 million in 2021, then dropped by 21.3% to -$279.0 million in 2022, then fell by 18.67% to -$331.1 million in 2023, then crashed by 69.09% to -$559.9 million in 2024, then skyrocketed by 48.67% to -$287.4 million in 2025.
- Business Quant data shows Enterprise Value for KROS at -$287.4 million in Q4 2025, -$693.5 million in Q3 2025, and -$690.2 million in Q2 2025.